NASDAQ:OPNT - Opiant Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $42.00
  • Forecasted Upside: 411.57 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$8.21
▼ -0.42 (-4.87%)
1 month | 3 months | 12 months
Get New Opiant Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OPNT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OPNT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$42.00
▲ +411.57% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Opiant Pharmaceuticals in the last 3 months. The average price target is $42.00, with a high forecast of $42.00 and a low forecast of $42.00. The average price target represents a 411.57% upside from the last price of $8.21.
Buy
The current consensus among 1 polled investment analysts is to buy stock in Opiant Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/24/2020

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/1/2020Northland SecuritiesReiterated RatingBuy$42.00High
i
11/7/2019Northland SecuritiesReiterated RatingBuy$42.00Medium
i
Rating by Carl Byrnes at Northland Securities
10/18/2019Northland SecuritiesReiterated RatingBuy$42.00Medium
i
8/2/2019Northland SecuritiesReiterated RatingBuyHigh
i
5/29/2019Northland SecuritiesInitiated CoverageOutperform ➝ Outperform$42.00High
i
10/4/2018Cantor FitzgeraldSet Price TargetBuy$42.00Low
i
Rating by Brandon Folkes at Cantor Fitzgerald
9/28/2018Cantor FitzgeraldSet Price TargetOverweight ➝ Buy$32.00 ➝ $42.00Medium
i
Rating by Brandon Folkes at Cantor Fitzgerald
8/28/2018Cantor FitzgeraldSet Price TargetBuy$32.00High
i
Rating by Brandon Folkes at Cantor Fitzgerald
8/9/2018Cantor FitzgeraldSet Price TargetBuy$32.00High
i
Rating by Brandon Folkes at Cantor Fitzgerald
7/30/2018Cantor FitzgeraldSet Price TargetBuy$32.00Medium
i
Rating by Brandon Folkes at Cantor Fitzgerald
6/14/2018Cantor FitzgeraldReiterated RatingOverweightLow
i
Rating by B. Folkes at Cantor Fitzgerald
6/11/2018Cantor FitzgeraldInitiated CoverageBuy$32.00High
i
11/26/2015Evercore ISILower Price TargetOutperform$42.00 ➝ $32.00N/A
i
11/26/2015B. RileyUpgradeNeutral ➝ BuyN/A
i
(Data available from 11/25/2015 forward)
Opiant Pharmaceuticals logo
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for opioid overdose; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California.
Read More

Today's Range

Now: $8.21
$8.07
$8.59

50 Day Range

MA: $7.57
$6.87
$8.88

52 Week Range

Now: $8.21
$6.79
$15.68

Volume

47,216 shs

Average Volume

36,494 shs

Market Capitalization

$34.96 million

P/E Ratio

4.77

Dividend Yield

N/A

Beta

0.74